Pipeline

We are building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases

  • Discovery /Pre-clinical
  • Phase I
  • Phase II
  • PIVOTAL OR PHASE III

        STATUS/ANTICIPATED MILESTONES

anti-IL-4Rα mAb (Th2 cell modulator)

Atopic Dermatitis (AD) - China
Atopic Dermatitis (AD) - Global
Asthma - Global
  •  
  •  
  •  
  •  
  • Commercial partner Simcere having ongoing regulatory discussions with CDE; Update expected as early as Q2’24
  • FDA Type C meeting in Q2’24
  • Positive global Ph2b trial data; FDA EoP2 meeting in Q2’24

Small molecule targeting S1P1 (Th1 cell modulator)

Ulcerative Colitis
  •  
  •  
  •  
  •  
Crohn's Disease
  •  
  •  
  •  
  •  
  • Positive UC maintenance data reported                           
  • Seeking partnerships to advance into future trials for both indications

Peripherally restricted H3 receptor antagonist

Pruritis
  •  
  •  
  •  
  •  
  • First-in-Human completed

CBP-233

 anti-IL-33 mAb

Type 2 Inflammatory Diseases
  •  
  •  
  •  
  •  
  • To initiate IND-enabling studies in 2025

CBP-246

anti-IL-1RAcP mAb

Type 2 Inflammatory Diseases
  •  
  •  
  •  
  •  
  • To initiate IND-enabling studies in 2025

CBP-403

Bispecific anti-Th2 cytokines mAb

  •  
  •  
  •  
  •  
Type 2 Inflammatory Diseases
  • Development candidate nomination in 2024
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors